Across TCGA pan-cancer cohorts, TMPRSS12 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated TMPRSS12 data layer compared with 21 for mass-spec protein.
The strongest signal is observed in kidney chromophobe (KICH), where higher TMPRSS12 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated TMPRSS12 expression acts as an unfavorable survival marker.
KICH, LIHC, and UCEC are the cancer types where TMPRSS12 Mutation most reproducibly stratifies survival.